|
Minaprine
drug data and news
Minaprine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Minaprine
|
| Brand Names/Synonyms |
AGR 620; Brantur; Cantor; MINAPRINE HYDROCHLORIDE; Minaprina [Inn-Spanish]; Minaprine; Minaprine Dihydrochloride; Minaprine Hydrochloride [Usan]; Minaprine [Usan:Ban:Inn]; Minaprinum [Inn-Latin] |
| Indication |
For the treatment of depression |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain. Similar to other antidepressant treatments, minaprine attenuates the beta-adrenergic receptor function. Studies have also shown that minaprine improves memory consolidation and that repeated drug administration leads to potentiation of this effect. Moreover, the effects of minaprine on memory consolidation are related to its dopaminergic action. |
| Mechanism Of Action |
Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. |
Minaprine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Not Available |
| Drug_Category |
Antiparkinson Agents; Antidepressive Agents; Central Nervous System Agents; Monoamine Oxidase Inhibitors; ATC:N06AX07 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
4-methyl-N-(2-morpholin-4-ylethyl)-6-phenyl-pyridazin-3-amine |
| Chemical Formula |
C17H22N4O |
| Molecular Weight |
298.383 g/mol |
| Smiles String |
CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3 |
| Melting Point |
122 °C |
| Water Solubility |
2360 mg/L |
| State |
Solid |
| LogP/Hphobicity |
1.157 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Hepatic. Cytochrome P4502D is responsible for the 4-hydroxylation of minaprine to 4-hydroxyminaprine. |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00735 |
| CAS Registry Number |
25905-77-5 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
SID:213627 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
